<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182958</url>
  </required_header>
  <id_info>
    <org_study_id>263-102-00006</org_study_id>
    <secondary_id>2019-001968-29</secondary_id>
    <nct_id>NCT04182958</nct_id>
  </id_info>
  <brief_title>A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects</brief_title>
  <official_title>A Phase I, Open-Label Trial to Assess the Mass Balance and Pharmacokinetics of a Single Intravenous Administration of (14C)-OPC-61815 to Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine the mass balance of totalradioactivity following a single IV infusionof&#xD;
           (14C)-OPC-61815.&#xD;
&#xD;
        -  To determine routes and rates of elimination of total radioactivity following a single&#xD;
           IV infusion of (14C)-OPC-61815&#xD;
&#xD;
        -  To assess the PK of total radioactivity in plasma and whole blood following a single IV&#xD;
           infusion of (14C)-OPC-61815&#xD;
&#xD;
        -  To assess the PK of OPC-61815 free form and OPC-41061 in plasma following a single IV&#xD;
           infusion of (14C)-OPC-61815&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) - Plasma OPC-61815 Free Form</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Peak Concentration (Cmax) - Plasma OPC-61815 Free Form</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-phase Elimination Half-life (t1/2,z) - Plasma OPC-61815 Free Form</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞ - Plasma OPC-41061</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Plasma OPC-41061</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2,z - Plasma OPC-41061</measure>
    <time_frame>48 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞ - Plasma Total Radioactivity</measure>
    <time_frame>168 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Plasma Total Radioactivity</measure>
    <time_frame>168 hours after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2,z - Plasma Total Radioactivity</measure>
    <time_frame>168 hours after dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>(14C)-OPC-61815</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(14C)-OPC-61815</intervention_name>
    <description>On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815</description>
    <arm_group_label>(14C)-OPC-61815</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects between 35 and 55 years of age, inclusive; hold a valid Japanese&#xD;
             passport and be first generation Japanese, defined as the subject, the subject's&#xD;
             biological parent, and all of the subject's biological grandparents being of exclusive&#xD;
             Japanese descent, have been born in Japan, and not lived outside of Japan for more&#xD;
             than 5 years; with a body mass index between 18.5 and 28.0 kg/m2, inclusive, and a&#xD;
             total body weight between 50 and 100 kg, inclusive; in good health, determined by no&#xD;
             clinically significant findings from medical history, physical examination, 12-lead&#xD;
             electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations&#xD;
             at Screening and Check in as assessed by the investigator (or designee); and have a&#xD;
             history of a minimum of 1 bowel movement per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion; poor peripheral venous access; participation in a&#xD;
             clinical trial involving administration of an investigational drug in the past 90 days&#xD;
             prior to dosing; subjects with exposure to significant diagnostic or therapeutic&#xD;
             radiation or current employment in a job requiring radiation exposure monitoring&#xD;
             within 12 months prior to Check-in; subjects who have participated in any clinical&#xD;
             trial involving a radiolabeled investigational drug within 12 months prior to&#xD;
             Check-in.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <results_first_submitted>September 8, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Small studies with less than 25 participants are excluded from data sharing.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04182958/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04182958/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall: (14C)-OPC-61815</title>
          <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall: (14C)-OPC-61815</title>
          <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) - Plasma OPC-61815 Free Form</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) - Plasma OPC-61815 Free Form</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2060" spread="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Peak Concentration (Cmax) - Plasma OPC-61815 Free Form</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Peak Concentration (Cmax) - Plasma OPC-61815 Free Form</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1500" spread="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal-phase Elimination Half-life (t1/2,z) - Plasma OPC-61815 Free Form</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal-phase Elimination Half-life (t1/2,z) - Plasma OPC-61815 Free Form</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞ - Plasma OPC-41061</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞ - Plasma OPC-41061</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1150" spread="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Plasma OPC-41061</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Plasma OPC-41061</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2,z - Plasma OPC-41061</title>
        <time_frame>48 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,z - Plasma OPC-41061</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞ - Plasma Total Radioactivity</title>
        <time_frame>168 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞ - Plasma Total Radioactivity</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>h*ngEq/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30300" spread="4850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Plasma Total Radioactivity</title>
        <time_frame>168 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Plasma Total Radioactivity</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>ngEq/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2180" spread="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2,z - Plasma Total Radioactivity</title>
        <time_frame>168 hours after dose</time_frame>
        <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall: (14C)-OPC-61815</title>
            <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,z - Plasma Total Radioactivity</title>
          <population>The PK population included all subjects that received (14C)-OPC-61815 (full dose within the time frame of 55 to 65 minutes, inclusive) and had evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from the start of investigational medicinal product (IMP) administration up to 12 days</time_frame>
      <desc>The safety population included all subjects that received (14C)-OPC-61815.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall: (14C)-OPC-61815</title>
          <description>Subjects were to receive a single IV infusion of 16 mg (14C)-OPC-61815, containing approximately 75.1 μCi (2.78 MBq), over a period of 60 minutes (55 to 65 minutes, inclusive) on Day 1 of the trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Ver. 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., LTD.</organization>
      <phone>+81-3-6361-7366</phone>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

